Quick Takeaways
- Avoro Capital Advisors LLC filed SCHEDULE 13G/A for AMICUS THERAPEUTICS, INC. Common Stock, par value $0.01 per share (FOLD).
- Disclosed ownership: 4.9%.
- Date of event: 30 Sep 2025.
Avoro Capital Advisors LLC - 30 Sep 2025 SCHEDULE 13G/A Report for AMICUS THERAPEUTICS, INC. Common Stock, par value $0.01 per share (FOLD)
- Filing Manager
- Avoro Capital Advisors LLC
- Reporting Manager
- Avoro Capital Advisors LLC
- Symbol
- FOLD
- Shares outstanding
- 308,521,561 shares
- Disclosed Ownership
- 15,025,000 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 09:06:50 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 15 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Avoro Capital Advisors LLC disclosed 4.9% ownership in AMICUS THERAPEUTICS, INC. Common Stock, par value $0.01 per share (FOLD) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 15 May 2025.
- Current filing was accepted on 14 Nov 2025, 09:06.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 4.9% | 15,025,000 | 15,025,000 | 0 | /s/ Scott Epstein | Scott Epstein, Chief Operating Officer & Chief Compliance Officer | |
| Behzad Aghazadeh | 4.9% | 15,025,000 | 15,025,000 | 0 | /s/ Behzad Aghazadeh | Behzad Aghazadeh, Individually |